Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 10/20 | 0.37 |
| ▸ | PPARA | Q07869 | 3/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 5/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6976751 | 0.89 | HTR2C (0.38) | SRD5A1ESR1ESR2 | |
| SCHEMBL6978852 | 0.80 | CA2 (0.45) | HTR6CA1CA2 | |
| SCHEMBL14143008 | 0.80 | CA2 (0.45) | HTR6CA1CA2 | |
| SCHEMBL7216117 | 0.77 | MTNR1A (0.50) | PPARDCA1CA2CA9CA14 | |
| SCHEMBL17321040 | 0.76 | CA2 (0.52) | CA2 | |
| SCHEMBL12086024 | 0.76 | SRD5A1 (0.46) | SRD5A1PPARDPPARAESR1ESR2 | |
| SCHEMBL7220825 | 0.75 | HTR2C (0.44) | SRD5A1ESR1ESR2SLC6A4 | |
| SCHEMBL9630429 | 0.74 | MTNR1A (0.56) | — | |
| SCHEMBL17361445 | 0.74 | METAP1 (0.31) | SRD5A1SLC6A4 | |
| SCHEMBL17361869 | 0.74 | FFAR1 (0.41) | PPARDPPARACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174974-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150148313-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148313-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | F7, F12, F5 | SRD5A1 849/4885PPARD 3597/4885PPARA 3519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.